Study on the Predictive Value of the Natural Calcium Isotope Ratio in Urine and Serum for the Diagnosis of Osteoporosis
NCT ID: NCT02967978
Last Updated: 2021-02-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
130 participants
OBSERVATIONAL
2016-11-22
2019-08-16
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of the Diagnostic Value of Stable Calcium Isotope Profiling in Bone and Calcium Disorders
NCT02252679
Case Control Study: Determinants of Osteoporosis in GOLD II COPD Patients.
NCT00725673
Quality of the Detection & Treatment of Osteoporotic Fractures in a Swiss Trauma Center
NCT02157753
Osteoporosis and Knee Insufficiency Fracture
NCT02332681
OSTPRE-Fracture Prevention Study
NCT00592917
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
By an individual screening 100 women will be included in the study who are characterized concerning existing or non-existing osteoporosis according to the guidelines of DVO 2014 and ISCD 2015, respectively.
According to the EPOS study results the prevalence of osteoporosis in Germany in postmenopausal women aged 50 to 60 years is about 15% and at the age of more than 70 years about 45%. In case of risk factors, such as hip fracture of father and/or mother, smoking, lactose intolerance, vegan nutrition, underweight (BMI \< 20), diabetes, intake of loop diuretics, glucocorticoids, aromatase inhibitors and proton pump inhibitors a higher prevalence can be assumed. Thus by electing women with at least one risk factor of osteoporosis a higher proportion may meet the criteria of osteoporosis.
Since some women are expected to present with low vitamin D levels and so far are expected to present with osteomalacia, and since other exclusion criteria may occur, N = 100 women will be investigated, in order to obtain data from N = 80 women who may meet the criteria of the target group (about N = 40 with osteoporosis and about N = 40 without osteoporosis (normal control).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age 50 - 75 years
* Fullfilling the criteria for diagnostic examination for osteoporosis incl. DXA according to DVO/ZÄS list 2015
* Written informed consent
Exclusion Criteria
* DXA within the last 12 month before inclusion
* Substitution with sex hormones
* Substitution with non-identified calcium supplements
* Vitamin D deficiency (post-hoc stratifying and exclusion from primary analysis, respectively)
* Hyperparathyreoidism (by history and based on calcium, phosphate and chloride in serum
* known renal failure
* known cancer disease
* Current enrollement in a clinical intervention trial
* Enrollement in a clinical intervention trial within the last 4 weeks
* Severe cognitive or psychiatric disorder
* Scheduled hospitalisation before the radiological examination (DXA)
* Legal incapacity
50 Years
75 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Kiel
OTHER
Clinical Research Center Kiel GmbH
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dr. Christiane Laue, MD
Dr. med (medical doctor)
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Christiane Laue, Dr. med
Role: PRINCIPAL_INVESTIGATOR
Clinical Research Center Kiel GmbH
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Clinical Research Center Kiel GmbH
Kiel, Schleswig-Holstein, Germany
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GEO-Osteo-2016
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.